Mesalamine 800 mg delayed-release tablets have been launched, and FDA approval has been granted for lenalidomide, with plans for entry into the U.S. generic market in 2026.
FDA grants IND clearance to Zabalafin Hydrogel, a botanical drug targeting bacterial, inflammatory, and pruritic components of atopic dermatitis, following successful Phase 2a trials.
The drug development tool offers an alternative, clinically meaningful endpoint in clinical trials that evaluate pharmacologic treatments for alcohol use disorder.
FDA approves GSK’s Penmenvy, a 5-in-1 meningococcal vaccine for adolescents and young adults, targeting five major serogroups of Neisseria meningitidis that cause invasive meningococcal disease.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
FDA approves Merilog (insulin-aspart-szjj) as the first rapid-acting insulin biosimilar to Novolog for glycemic control in adult and pediatric diabetes patients, expanding treatment accessibility.
An outbreak of measles in Gaines County, Texas, has led to at least 24 reported cases, with none of the infected individuals being vaccinated, sparking concerns of potential further spread in the community.
The FDA has approved Evolysse Form and Smooth, the latest hyaluronic acid fillers. Their approval "represent[s] the first major technological breakthrough in hyaluronic acid dermal fillers in a decade," noted the manufacturer.
A Connecticut psychiatrist agreed to a $455K settlement after an investigation identified fraudulent Medicare claims and unsafe controlled substance prescribing practices, resulting in DEA sanctions and a 20-year exclusion from federal health programs.